Detalhe da pesquisa
1.
Deferasirox chelation therapy in patients with transfusion-dependent MDS: a 'real-world' report from two regional Italian registries: Gruppo Romano Mielodisplasie and Registro Basilicata.
Eur J Haematol
; 95(1): 52-6, 2015 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-25764148
2.
Deferasirox in the treatment of iron overload during myeloproliferative neoplasms in fibrotic phase: does ferritin decrement matter?
Leuk Res
; 76: 65-69, 2019 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-30578958
3.
Imatinib and polypharmacy in very old patients with chronic myeloid leukemia: effects on response rate, toxicity and outcome.
Oncotarget
; 7(48): 80083-80090, 2016 Nov 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-27579540
4.
Age influences initial dose and compliance to imatinib in chronic myeloid leukemia elderly patients but concomitant comorbidities appear to influence overall and event-free survival.
Leuk Res
; 38(10): 1173-6, 2014 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-25047978
5.
Revised International Prognostic Scoring System (IPSS) predicts survival and leukemic evolution of myelodysplastic syndromes significantly better than IPSS and WHO Prognostic Scoring System: validation by the Gruppo Romano Mielodisplasie Italian Regional Database.
J Clin Oncol
; 31(21): 2671-7, 2013 Jul 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-23796988
6.
Imatinib in very elderly patients with chronic myeloid leukemia in chronic phase: a retrospective study.
Drugs Aging
; 30(8): 629-37, 2013 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-23681399